Search Results - "Pabla, Sarabjot"

Clinical and Biologic Correlates of ADORA2A Transcriptomic Expression in Cancer by Shreenivas, Aditya, Nishizaki, Daisuke, Lee, Suzanna, Pabla, Sarabjot, Nesline, Mary, Conroy, Jeffrey M, DePietro, Paul, Kato, Shumei, Kurzrock, Razelle

“…ADORA2A (adenosine A2a receptor) and ADORA2B propagate immunoregulatory signals, including restricting both innate and adaptive immunity, though recent data…”
Get full text

A scalable high-throughput targeted next-generation sequencing assay for comprehensive genomic profiling of solid tumors by Conroy, Jeffrey M, Pabla, Sarabjot, Glenn, Sean T, Seager, R J, Van Roey, Erik, Gao, Shuang, Burgher, Blake, Andreas, Jonathan, Giamo, Vincent, Mallon, Melissa, Lee, Yong Hee, DePietro, Paul, Nesline, Mary, Wang, Yirong, Lenzo, Felicia L, Klein, Roger, Zhang, Shengle

“…Timely and accurate identification of molecular alterations in solid tumors is essential for proper management of patients with advanced cancers. This has…”
Get full text

Analytical Validation of a Next-Generation Sequencing Assay to Monitor Immune Responses in Solid Tumors by Conroy, Jeffrey M., Pabla, Sarabjot, Glenn, Sean T., Burgher, Blake, Nesline, Mary, Papanicolau-Sengos, Antonios, Andreas, Jonathan, Giamo, Vincent, Lenzo, Felicia L., Hyland, Fiona C.L., Omilian, Angela, Bshara, Wiam, Qin, Moachun, He, Ji, Puzanov, Igor, Ernstoff, Marc S., Gardner, Mark, Galluzzi, Lorenzo, Morrison, Carl

“…We have developed a next-generation sequencing assay to quantify biomarkers of the host immune response in formalin-fixed, paraffin-embedded (FFPE) tumor…”
Get full text

Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden by Morrison, Carl, Pabla, Sarabjot, Conroy, Jeffrey M, Nesline, Mary K, Glenn, Sean T, Dressman, Devin, Papanicolau-Sengos, Antonios, Burgher, Blake, Andreas, Jonathan, Giamo, Vincent, Qin, Moachun, Wang, Yirong, Lenzo, Felicia L, Omilian, Angela, Bshara, Wiam, Zibelman, Matthew, Ghatalia, Pooja, Dragnev, Konstantin, Shirai, Keisuke, Madden, Katherine G, Tafe, Laura J, Shah, Neel, Kasuganti, Deepa, de la Cruz-Merino, Luis, Araujo, Isabel, Saenger, Yvonne, Bogardus, Margaret, Villalona-Calero, Miguel, Diaz, Zuanel, Day, Roger, Eisenberg, Marcia, Anderson, Steven M, Puzanov, Igor, Galluzzi, Lorenzo, Gardner, Mark, Ernstoff, Marc S

“…Immune checkpoint inhibitors (ICIs) have changed the clinical management of melanoma. However, not all patients respond, and current biomarkers including PD-L1…”
Get full text

LAG‐3 transcriptomic expression patterns across malignancies: Implications for precision immunotherapeutics by Adashek, Jacob J., Kato, Shumei, Nishizaki, Daisuke, Miyashita, Hirotaka, De, Pradip, Lee, Suzanna, Pabla, Sarabjot, Nesline, Mary, Conroy, Jeffrey M., DePietro, Paul, Lippman, Scott, Kurzrock, Razelle

“…Background Lymphocyte activation gene 3 (LAG‐3) or CD223 is a transmembrane protein that serves as an immune checkpoint which attenuates T‐cell activation…”
Get full text

Mechanisms of immune modulation in the tumor microenvironment and implications for targeted therapy by Czajka-Francuz, Paulina, Prendes, Maria J, Mankan, Arun, Quintana, Ángela, Pabla, Sarabjot, Ramkissoon, Shakti, Jensen, Taylor J, Peiró, Sandra, Severson, Eric A, Achyut, Bhagelu R, Vidal, Laura, Poelman, Martine, Saini, Kamal S

“…The efficacy of cancer therapies is limited to a great extent by immunosuppressive mechanisms within the tumor microenvironment (TME). Numerous immune escape…”
Get full text

Cancer testis antigen burden (CTAB): a novel biomarker of tumor-associated antigens in lung cancer by Seager, R J, Senosain, Maria-Fernanda, Van Roey, Erik, Gao, Shuang, DePietro, Paul, Nesline, Mary K, Dash, Durga Prasad, Zhang, Shengle, Ko, Heidi, Hastings, Stephanie B, Strickland, Kyle C, Previs, Rebecca A, Jensen, Taylor J, Eisenberg, Marcia, Caveney, Brian J, Severson, Eric A, Ramkissoon, Shakti, Conroy, Jeffrey M, Pabla, Sarabjot

“…Cancer-testis antigens (CTAs) are tumor antigens that are normally expressed in the testes but are aberrantly expressed in several cancers. CTA overexpression…”
Get full text

Real-world comprehensive genomic and immune profiling reveals distinct age- and sex-based genomic and immune landscapes in tumors of patients with non-small cell lung cancer by Wallen, Zachary D, Ko, Heidi, Nesline, Mary K, Hastings, Stephanie B, Strickland, Kyle C, Previs, Rebecca A, Zhang, Shengle, Pabla, Sarabjot, Conroy, Jeffrey, Jackson, Jennifer B, Saini, Kamal S, Jensen, Taylor J, Eisenberg, Marcia, Caveney, Brian, Sathyan, Pratheesh, Severson, Eric A, Ramkissoon, Shakti H

“…Younger patients with non-small cell lung cancer (NSCLC) (<50 years) represent a significant patient population with distinct clinicopathological features and…”
Get full text

Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients by Pabla, Sarabjot, Conroy, Jeffrey M, Nesline, Mary K, Glenn, Sean T, Papanicolau-Sengos, Antonios, Burgher, Blake, Hagen, Jacob, Giamo, Vincent, Andreas, Jonathan, Lenzo, Felicia L, Yirong, Wang, Dy, Grace K, Yau, Edwin, Early, Amy, Chen, Hongbin, Bshara, Wiam, Madden, Katherine G, Shirai, Keisuke, Dragnev, Konstantin, Tafe, Laura J, Marin, Daniele, Zhu, Jason, Clarke, Jeff, Labriola, Matthew, McCall, Shannon, Zhang, Tian, Zibelman, Matthew, Ghatalia, Pooja, Araujo-Fernandez, Isabel, Singavi, Arun, George, Ben, MacKinnon, Andrew Craig, Thompson, Jonathan, Singh, Rajbir, Jacob, Robin, Dressler, Lynn, Steciuk, Mark, Binns, Oliver, Kasuganti, Deepa, Shah, Neel, Ernstoff, Marc, Odunsi, Kunle, Kurzrock, Razelle, Gardner, Mark, Galluzzi, Lorenzo, Morrison, Carl

“…Resistance to immune checkpoint inhibitors (ICIs) has been linked to local immunosuppression independent of major ICI targets (e.g., PD-1). Clinical experience…”
Get full text

Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors by Conroy, Jeffrey M, Pabla, Sarabjot, Nesline, Mary K, Glenn, Sean T, Papanicolau-Sengos, Antonios, Burgher, Blake, Andreas, Jonathan, Giamo, Vincent, Wang, Yirong, Lenzo, Felicia L, Bshara, Wiam, Khalil, Maya, Dy, Grace K, Madden, Katherine G, Shirai, Keisuke, Dragnev, Konstantin, Tafe, Laura J, Zhu, Jason, Labriola, Matthew, Marin, Daniele, McCall, Shannon J, Clarke, Jeffrey, George, Daniel J, Zhang, Tian, Zibelman, Matthew, Ghatalia, Pooja, Araujo-Fernandez, Isabel, de la Cruz-Merino, Luis, Singavi, Arun, George, Ben, MacKinnon, Alexander C, Thompson, Jonathan, Singh, Rajbir, Jacob, Robin, Kasuganti, Deepa, Shah, Neel, Day, Roger, Galluzzi, Lorenzo, Gardner, Mark, Morrison, Carl

“…PD-L1 immunohistochemistry (IHC) has been traditionally used for predicting clinical responses to immune checkpoint inhibitors (ICIs). However, there are at…”
Get full text

Case report: Single gene testing and comprehensive genomic profiling in non-small cell lung cancer—a case series of divergent results from a large reference laboratory by Strickland, Kyle C., Nesline, Mary K., Previs, Rebecca A., Ko, Heidi, Cooper, Maureen, Rushton, Jennifer R., Wallen, Zachary D., Pabla, Sarabjot, Conroy, Jeffrey M., Sausen, Mark, Saini, Kamal S., Cantini, Luca, Jensen, Taylor J., Caveney, Brian J., Eisenberg, Marcia, Severson, Eric A., Ramkissoon, Shakti

“…Clinical management of non-small cell lung cancer (NSCLC) requires accurate identification of tumor-specific genetic alterations to inform treatment options…”
Get full text

High CTLA-4 transcriptomic expression correlates with high expression of other checkpoints and with immunotherapy outcome by Krishnamurthy, Nithya, Nishizaki, Daisuke, Lippman, Scott M, Miyashita, Hirotaka, Nesline, Mary K, Pabla, Sarabjot, Conroy, Jeffrey M, DePietro, Paul, Kato, Shumei, Kurzrock, Razelle

“…CTLA-4 impedes the immune system's antitumor response. There are two Food and Drug Administration-approved anti-CTLA-4 agents - ipilimumab and tremelimumab -…”
Get full text

Pan‐cancer analysis of TIM‐3 transcriptomic expression reveals high levels in pancreatic cancer and interpatient heterogeneity by Lim, Jungah, Kurzrock, Razelle, Nishizaki, Daisuke, Miyashita, Hirotaka, Adashek, Jacob J., Lee, Suzanna, Pabla, Sarabjot, Nesline, Mary, Conroy, Jeffrey M., DePietro, Paul, Lippman, Scott M., Kato, Shumei

“…Background T‐cell immunoglobulin and mucin domain‐containing protein 3 (TIM‐3), an immune checkpoint receptor, dampens immune function. TIM‐3 antagonists have…”
Get full text

Development and analytical validation of a next-generation sequencing based microsatellite instability (MSI) assay by Pabla, Sarabjot, Andreas, Jonathan, Lenzo, Felicia L, Burgher, Blake, Hagen, Jacob, Giamo, Vincent, Nesline, Mary K, Wang, Yirong, Gardner, Mark, Conroy, Jeffrey M, Papanicolau-Sengos, Antonios, Morrison, Carl, Glenn, Sean T

“…We have developed and analytically validated a next-generation sequencing (NGS) assay to classify microsatellite instability (MSI) in formalin-fixed…”
Get full text

T-cell priming transcriptomic markers: implications of immunome heterogeneity for precision immunotherapy by Miyashita, Hirotaka, Kurzrock, Razelle, Bevins, Nicholas J., Thangathurai, Kartheeswaran, Lee, Suzanna, Pabla, Sarabjot, Nesline, Mary, Glenn, Sean T., Conroy, Jeffrey M., DePietro, Paul, Rubin, Eitan, Sicklick, Jason K., Kato, Shumei

“…Immune checkpoint blockade is effective for only a subset of cancers. Targeting T-cell priming markers (TPMs) may enhance activity, but proper application of…”
Get full text

4‐1BB transcriptomic expression patterns across malignancies: Implications for clinical trials of 4‐1BB agonists by Uehara, Yuji, Kato, Shumei, Nishizaki, Daisuke, Miyashita, Hirotaka, Lee, Suzanna, Nesline, Mary K., Pabla, Sarabjot, Conroy, Jeffrey M., DePietro, Paul, Ko, Heidi, Sicklick, Jason K., Kurzrock, Razelle

Get full text

High indoleamine 2,3-dioxygenase transcript levels predict better outcome after front-line cancer immunotherapy by Fujiwara, Yu, Kato, Shumei, Nishizaki, Daisuke, Miyashita, Hirotaka, Lee, Suzanna, Nesline, Mary K., Conroy, Jeffrey M., DePietro, Paul, Pabla, Sarabjot, Lippman, Scott M., Kurzrock, Razelle

“…Indoleamine 2,3-dioxygenase 1 (IDO1), which catabolizes tryptophan, is a potential target to unlock the immunosuppressive tumor microenvironment. Correlations…”
Get full text

PD-L2 amplification and durable disease stabilization in patient with urothelial carcinoma receiving pembrolizumab by George, Saby, Papanicolau-Sengos, Antonios, Lenzo, Felicia L, Conroy, Jeffrey M, Nesline, Mary, Pabla, Sarabjot, Glenn, Sean T, Burgher, Blake, Andreas, Jonathan, Giamo, Vincent, Qin, Moachun, Wang, Yirong, Galluzzi, Lorenzo, Morrison, Carl

“…We report the immunological profile of a patient with upper-tract urothelial carcinoma experiencing stable disease on pembrolizumab for 20 months. The tumor…”
Get full text

Cytokeratin-8 in Anaplastic Thyroid Carcinoma: More Than a Simple Structural Cytoskeletal Protein by Guo, Dehuang, Xu, Qinqin, Pabla, Sarabjot, Koomen, John, Biddinger, Paul, Sharma, Ashok, Pabla, Simarjot, Pacholczyk, Rafal, Chang, Chien-Chung, Friedrich, Kevin, Mohammed, Kamran, Smallridge, Robert C, Copland, John A, She, Jin-Xiong, Weinberger, Paul M

“…Anaplastic thyroid carcinoma (ATC) is almost universally fatal. Elevated keratin-8 (KRT8) protein expression is an established diagnostic cancer biomarker in…”
Get full text

166 High CTLA-4 transcriptomic expression correlates with high expression of other checkpoints and with outcome on immune checkpoint inhibitors by Krishnamurthy, Nithya, Nishizaki, Daisuke, Lippman, Scott M, Miyashita, Hirotaka, Nesline, Mary K, Pabla, Sarabjot, Conroy, Jeffrey M, DePietro, Paul, Kato, Shumei, Kurzrock, Razelle

“…BackgroundCTLA-4 is a membrane glycoprotein expressed by activated effector T cells that impedes the immune system’s antitumor response. There are two…”
Get full text